However, a retrospective cohort study indicates that the group treated with SGLT2 inhibitors had a lower incidence of cancers than the group treated with dipeptidyl peptidase-4 inhibitors which are known to increase blood GLP-1 levels [31]. The gene discussed is DPP4; the disease is cancer.